160 Chapter 7 1. Veijalainen O, Kares S, Kotaniemi-Talonen L, Kujala P, Vuento R, Luukkaala T, et al. Primary HPV screening for cervical cancer: Results after two screening rounds in a regional screening program in Finland. Acta Obstetricia et Gynecologica Scandinavica 2020. 2. Louvanto K, Chevarie-Davis M, Ramanakumar AV, Franco EL, Ferenczy A. HPV testing with cytology triage for cervical cancer screening in routine practice. American Journal of Obstetrics and Gynecology 2014; 210(5): 474.e1-.e7. 3. Louvanto K, Eriksson T, Gray P, Apter D, Baussano I, Bly A, et al. Baseline findings and safety of infrequent vs. frequent screening of human papillomavirus vaccinated women. Int J Cancer 2020; 147(2): 440-7. 4. Falcaro M, Castañon A, Ndlela B, Checchi M, Soldan K, Lopez-Bernal J, et al. The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational study. Lancet 2021; 398(10316): 2084-92. 5. Patel C, Brotherton JM, Pillsbury A, Jayasinghe S, Donovan B, Macartney K, et al. The impact of 10 years of human papillomavirus (HPV) vaccination in Australia: what additional disease burden will a nonavalent vaccine prevent? Euro Surveill 2018; 23(41). 6. El-Zein M, Richardson L, Franco EL. Cervical cancer screening of HPV vaccinated populations: Cytology, molecular testing, both or none. Journal of Clinical Virology 2016; 76: S62-S8. 7. Lei J, Ploner A, Lehtinen M, Sparén Pr, Dillner J, Elfström KM. Impact of HPV vaccination on cervical screening performance: a population-based cohort study. British Journal of Cancer 2020; 123(1): 155-60. 8. Louvanto K, Franco EL, Ramanakumar AV, Vasiljević, Na, Scibior-Bentkowska D, Koushik A, et al. Methylation of viral and host genes and severity of cervical lesions associated with human papillomavirus type 16. International Journal of Cancer 2015; 136(6): E638-E45. 9. Brentnall AR, Vasiljevic N, ScibiorBentkowska D, Cadman L, Austin J, Szarewski A, et al. A DNA methylation classifier of cervical precancer based on human papillomavirus and human genes. Int J Cancer 2014. 10. Kelly H, Benavente Y, Pavon MA, De Sanjose S, Mayaud P, Lorincz AT. Performance of DNA methylation assays for detection of high-grade cervical intraepithelial neoplasia (CIN2+): a systematic review and meta-analysis. Br J Cancer 2019; 121(11): 954-65. 11. Vink FJ, Meijer C, Clifford GM, Poljak M, Oštrbenk A, Petry KU, et al. FAM19A4/ miR124-2 methylation in invasive cervical cancer: A retrospective cross-sectional worldwide study. Int J Cancer 2020; 147(4): 1215-21. 12. Vink FJ, Lissenberg-Witte BI, Meijer C, Berkhof J, van Kemenade FJ, Siebers AG, et al. FAM19A4/miR124-2 methylation analysis as a triage test for HPV-positive women: cross-sectional and longitudinal data from a Dutch screening cohort. Clin Microbiol Infect 2021; 27(1): 125.e1-.e6. 13. Bonde J, Floore A, Ejegod D, Vink FJ, Hesselink A, van de Ven PM, et al. Methylation markers FAM19A4 and miR124-2 as triage strategy for primary human papillomavirus screen positive women: A large European multicenter study. Int J Cancer 2021; 148(2): 396-405. 14. Banila C, Lorincz AT, Scibior-Bentkowska D, Clifford GM, Kumbi B, Beyene D, et al. Clinical performance of methylation as a biomarker for cervical carcinoma in situ and cancer diagnosis: A worldwide study. 2022. REFERENCES
RkJQdWJsaXNoZXIy MjY0ODMw